title: Differing standards for the NIH Stem Cell Registry and FDA approval render most federally funded hESC lines unsuitable for clinical use.
authors: Institute for Stem Cell and Regenerative Medicine, University of Washington, Seattle, WA 98115, USA. Electronic address: ejonlin@u.washington.edu.
authors: Erica C
authors: EC
authors: Jonlin
mesh_terms: D002460:Cell Line; D002986:Clinical Trials as Topic; D053595:Embryonic Stem Cells / Q000166:cytology*; D005380:Financing, Government / Q000331:legislation & jurisprudence*; D006801:Humans; D009316:National Institutes of Health (U.S.); D012042:Registries / Q000592:standards*; D057905:Stem Cell Research / Q000941:ethics / Q000331:legislation & jurisprudence*; D014481:United States; D014486:United States Food and Drug Administration / Q000331:legislation & jurisprudence*